3.18
-1.24%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tianjin Chase Sun Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 300026.SZ. It has been listed since 30 October 2009. In the fiscal year to 31 December 2024, it reported revenue of CN¥5.78bn and net income of CN¥21.5m. At that date it held total assets of CN¥11.17bn and shareholders' equity of CN¥8.64bn.
Tianjin Chase Sun Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceutical products. The company is headquartered in Tianjin, Tianjin. The company went IPO on 2009-10-30. The firm's main products include Chinese traditional formula granules, Xuebijing injection, fasudil hydrochloride injection, low molecular weight heparin calcium injection, bulk drugs and excipient, among others. The firm also provides medical apparatus and instrument. The firm distributes its products in domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Oct 2009
- Employees
- 6,120
- Website
- chasesun.cn ↗
Leadership
Pay as last reported
- Mr. Wenyuan WuChairman of the Board, since 2024
- Mr. Wujun LanVice Chairman of the Board, General Manager, since 2011CN¥1.8m
- Mr. Wu SunFinance Director, Executive Deputy General Manager, Director, since 2019CN¥979,300
- Ms. Chunxu LiDeputy General Manager, Director, since 2019CN¥1.1m
- Mr. Ruiqiang ChenDeputy General ManagerCN¥1.2m
- Mr. Xiaozhong LuDeputy General ManagerCN¥1.8m
- Mr. Kun ZhangDeputy General ManagerCN¥1.3m
- Ms. Yi YangSecretary of the BoardCN¥521,800
- Ms. Juan ChenDirector
- Mr. Sen LinDirector
- Mr. Chen YaoDirector
- Mr. Tao GongIndependent DirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 25
- Environment
- 23
- Social
- 29
- Governance
- 22
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tianjin Chase Sun Pharmaceutical Co Ltd holds a dominant position in the pharmaceutical industry, with a strong market presence both domestically and internationally. This has enabled the company to enjoy a significant market share and establish long-standing relationships with key stakeholders.
- The company offers a diverse portfolio of pharmaceutical products, catering to various therapeutic areas. The wide product range allows Tianjin Chase Sun Pharmaceutical Co Ltd to serve a broad customer base and capitalize on multiple revenue streams.
Weaknesses
- Tianjin Chase Sun Pharmaceutical Co Ltd relies heavily on a few key suppliers for the procurement of raw materials and active pharmaceutical ingredients. Any disruption in the supply chain could negatively impact the company's production capabilities and result in delays or shortages.
- Despite its strong market position, the company has a relatively limited geographic presence compared to some of its global competitors. This restricts its access to certain markets and leaves it susceptible to fluctuations in regional economic conditions and regulatory environments.
Opportunities
- Tianjin Chase Sun Pharmaceutical Co Ltd has the opportunity to expand its presence in emerging markets, such as India and Southeast Asia, where there is a growing demand for affordable healthcare solutions. This expansion could drive additional revenue growth and diversify the company's revenue sources.
- By allocating resources to research and development efforts, Tianjin Chase Sun Pharmaceutical Co Ltd can enhance its portfolio with innovative and proprietary pharmaceutical products. This would not only boost its market competitiveness but also create opportunities for entering new therapeutic areas and addressing unmet medical needs.
Threats
- The pharmaceutical industry is highly competitive, with numerous established players and new entrants constantly vying for market share. Tianjin Chase Sun Pharmaceutical Co Ltd faces the challenge of staying ahead in a crowded market, where competitors offer similar products and compete on factors such as pricing, quality, and branding.
- Compliance with strict regulatory requirements is a persistent threat for Tianjin Chase Sun Pharmaceutical Co Ltd. Changes in regulations, such as drug safety standards or pricing regulations, can impact the company's operations, increase costs, or limit market access. Adapting to evolving regulations and maintaining compliance is crucial for sustained growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.